STM publisher IOS Press and the Bladder Cancer Advocacy Network (BCAN), have announced that the journal Bladder Cancer will now become the official journal of BCAN.
As the result of this new partnership, Bladder Cancer and BCAN will combine resources to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities. As such, the journal is dedicated to providing an open forum for publishing original peer-reviewed research in basic science, translational research and clinical medicine that will improve the fundamental understanding of bladder cancer and lead to more effective treatment of tumours of the bladder and upper urinary tract and improved patient outcomes.
Launched in 2015, Bladder Cancer is an international multidisciplinary journal designed to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumours of the bladder and upper urinary tract. Guided by an eminent editorial board comprising global leaders in the field, the journal publishes research reports, reviews, short communications, letters-to-the-editor, and special features that deliver timely commentary, alerts of groundbreaking research, clinical trials coverage, challenging case studies and access to current funding information.
Bladder cancer is the sixth most common cancer in the United States with over 79,000 new cases and nearly 17,000 deaths that were projected for 2017. With only recent advances in treatments over the past 30 years, there continues to be a tremendous need for more bladder cancer research.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
